Onychomycosis Pipeline Drugs Assessment

Posted by ahila on April 4th, 2018

Onychomycosis Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Onychomycosis Pipeline Drugs Assessment

Overview:

Onychomycosis is a fungal infection of fingernails or toenails, known as tinea unguium. Onychomycosis is common and occurs in about 10% of adult population. Nail changes may include, change in shape, brittleness, discoloration, debris trapped under the nail, detachment and thickening of the nail. Physicians can identify fungal nail infection by performing an examination most oftime. A sample may be taken from the debris beneath the nail and examined microscopically or cultured for possible fungal growth. Oral medications are generally required and sometimes they are combined with nail removal and/or application of nail lacquer. Presently available oral antifungal medications include: terbinafine, itraconazole, and fluconazole taken daily, in pulse or weekly, respectively.

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/onychomycosis-pipeline-drugs-assessment/#ulp-h4n2eZVGqb32xpPc

Segmentation:

By route of administration, onychomycosis pipeline drugs are segmented into

• Oral
• Topical
• Parenteral
• Others

By Trial Phase, Onychomycosis pipeline drugs are segmented as:

• Preclinical Trials
• Phase 1
• Phase 2
• Phase 3

By company, Onychomycosis pipeline drugs are segmented into

• Polichem S.A. (Switzerland)
• Hisamitsu Pharmaceutical Co., Inc. (Japan)
• Viamet Pharmaceuticals, Inc. (U.S.)
• Galderma S.A.
• Others

Space Analysis:

• In April 2017, Novan, Inc. announced positive top line results from the Company’s Phase-II clinical trial with SB208, as a broad-spectrum anti fungal gel for the treatment of superficial cutaneous fungal infections of the skin and nails, including tinea pedis and onychomycosis.
• In January 2017, Viamet Pharmaceuticals, Inc. announced positive results from RENOVATE, its Phase 2b clinical trial of VT-1161 in onychomycosis of the large toenail.

To view TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/onychomycosis-pipeline-drugs-assessment/#ulp-c654SbFYO64MsOhu